Drug therapy

Phase 3Small molecule

Drug therapy is one of 195 small molecule programs targeting Attention Deficit Hyperactivity Disorder. It is currently in Phase 3.

Indications

Total Trials

Active Trials

194

Competitors

Pipeline

Status by Indication[3][1]

Indication

Attention Deficit Hyperactivity DisorderActive, not recruiting

Benign Prostatic HyperplasiaActive, not recruiting

PneumoniaActive, not recruiting

Neuroendocrine CarcinomaActive, not recruiting

EncephalopathyActive, not recruiting

Ischemic StrokeActive, not recruiting

Attention Deficit Hyperactivity DisorderPhase 1

Active, not recruiting

Benign Prostatic HyperplasiaPhase 3

Active, not recruiting

PneumoniaPhase 1

Active, not recruiting

Neuroendocrine CarcinomaPhase 2

Active, not recruiting

EncephalopathyPreclinical

Active, not recruiting

Ischemic StrokePreclinical

Active, not recruiting

Competition

Competitive Landscape

547 competitors in Pneumonia

#DrugCompanyPhaseTrials

Drug therapy

MMassachusetts General Hospital

Phase 3

1 2

Jakafi

Incyte

Preclinical

1 3

Virazole

CConrado Roberto Hoffmann Filho

Preclinical

2 4

Zantac 150

CChattem

Preclinical

2 5

Prograf

VVeloxis Pharmaceuticals

Preclinical

1 6

Nexium

DDexcel Pharma Technologies Ltd.

Preclinical

1 7

Pepcid

KKenvue Brands

Preclinical

1 8

Aciphex

Akero Therapeutics

Preclinical

1 9

Protonix

WWyeth-Lederle Vaccines

Preclinical

1 10

Alka-Seltzer

AAbbott

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Elderly Patients

NCT06758037

Q2 2028

Phase 1Recruiting

Pneumonia

NCT06693362

Q2 2034

Recruiting

CAR

NCT06031610

Clinical

Trials by Indication[1]

Attention Deficit Hyperactivity Disorder1 trial

Cognitive Behavioral Therapy for Adult Attention Deficit Hyperactivity Disorder

Completed·MMassachusetts General Hospital·Phase 1·NCT00050050·40 enrolled

Benign Prostatic Hyperplasia1 trial

Prostatic Artery Embolization Versus Medical Treatment in Symptomatic Benign Prostatic Hyperplasia

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT02869971·90 enrolled

Elderly Patients1 trial

Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients with DLBCL Intolerant to Chemotherapy

Recruiting·FFirst Affiliated Hospital of Ningbo University·Phase 2·NCT06758037·50 enrolled

Neuromodulation1 trial

The Role of Neuromodulation Technique In Depression Disorder

Unknown status·SShanghai Mental Health Center·N/A·NCT05047159·450 enrolled

Adolescent1 trial

Cognitive Behavioral Therapy for Depression Relapse Prevention in Children and Adolescents

Completed·UUniversity of Texas Southwestern Medical Center·N/A·NCT00158301·72 enrolled

5 more indications

Encephalopathy1 trial

Early Diagnosis and Timely Treatment of Cirrhotic Patients With Minimal Hepatic Encephalopathy (CHESS-NCRCID 2106)

Unknown status·HHepatopancreatobiliary Surgery Institute of Gansu Province··NCT05140837·10,000 enrolled

CAR1 trial

Revascularization Effect on CSVD Burden in Carotid Artery Stenosis

Recruiting·ZZhejiang Provincial People's Hospital··NCT06031610·1,000 enrolled

Ischemic stroke1 trial

Predictors and Prognostic Factors on the Acute Ischemic Stroke

Terminated·TTongji Hospital··NCT03122002·1,200 enrolled

Pneumonia1 trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Uterine Blood Mesenchymal Stem Cells Injection for the Treatment of Severe Pneumonia Caused by Viruses

Recruiting·RRuijin Hospital·Phase 1·NCT06693362·60 enrolled

Neuroendocrine Carcinoma1 trial

Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas

Unknown status·LLei Li·Phase 2·NCT04635956·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Drug therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Drug therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Drug therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Massachusetts General Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMassachusetts General Hospital

Drug therapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q2 2028

Q2 2034

Trials by Indication[1]

Attention Deficit Hyperactivity Disorder1 trial

Benign Prostatic Hyperplasia1 trial

Elderly Patients1 trial

Neuromodulation1 trial

Adolescent1 trial

Encephalopathy1 trial

CAR1 trial

Ischemic stroke1 trial

Pneumonia1 trial

Neuroendocrine Carcinoma1 trial

References

Drug Info

Quick Facts

Related News